Craniosynostosis 4 (CRS4) Cell Models for Research

Craniosynostosis is a congenital condition characterized by premature fusion of one or more cranial sutures, occurring in approximately 1 in 2,000-2,500 live births worldwide (WHO, 2023). Craniosynostosis 4 (CRS4) is a rare subtype associated with mutations in the FGFR2 gene (OMIM 176943). The condition leads to abnormal skull shape, increased intracranial pressure, and potential neurodevelopmental deficits if untreated. Surgical intervention is the primary treatment, but long-term outcomes vary. The clinical impact is significant, with affected individuals requiring multidisciplinary care. Research focuses on understanding the molecular mechanisms to develop non-surgical therapies.

CRS4 serves as an ideal model for studying skeletal development and FGFR signaling. The disease is monogenic, with well-defined mutations in FGFR2, enabling precise genetic manipulation. Public datasets, such as those from the International Craniosynostosis Consortium, provide genomic and clinical data. Open questions include the differential effects of specific FGFR2 mutations on osteoblast differentiation and the potential for targeted therapies. Gene-edited cell models are essential for dissecting these pathways and testing therapeutic interventions.

The primary pathway involves FGFR2 signaling, which is critical for osteoblast proliferation and differentiation. Key steps include:

1. Ligand binding (FGFs) to FGFR2.

2. Receptor dimerization and autophosphorylation.

3. Activation of downstream signaling cascades, including MAPK/ERK, PI3K/AKT, and PLCγ.

4. Regulation of osteoblast-specific transcription factors (e.g., RUNX2, OSX).

Mutations in FGFR2, such as S252W or P253R, cause constitutive activation or altered ligand specificity, leading to premature osteoblast differentiation and suture fusion.

Data from ClinVar and COSMIC (v99).

The FGFR2 mutations hyperactivate several downstream networks:

• • MAPK/ERK pathway: Increased proliferation and differentiation.
• • PI3K/AKT pathway: Enhanced cell survival and metabolism.
• • PLCγ/Ca2+ signaling: Altered cytoskeletal dynamics.
• • RUNX2 and osteogenic gene expression: Upregulation of bone matrix proteins.

Key nodes include FGFR2, FRS2, GRB2, SOS1, RAS, RAF, MEK, ERK, PI3K, AKT, and mTOR.

Organoids derived from induced pluripotent stem cells (iPSCs) can recapitulate cranial suture development and are useful for studying FGFR2 mutations in a 3D context.

Animal models for CRS4 include:

• • Genetically engineered mouse models (GEMMs) carrying FGFR2 mutations (e.g., S252W knock-in) that exhibit craniosynostosis.
• • Patient-derived xenografts (PDX) are less common due to the non-cancerous nature of the disease but can be used for studying bone development.
• • Induced models using CRISPR to introduce mutations in mice are being developed.

These models are valuable for studying disease mechanisms and testing therapeutic interventions.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific FGFR2 mutations. For example:

• • FGFR2 S252W knock-in lines in hMSCs or MC3T3-E1 cells to model the gain-of-function mutation.
• • FGFR2 knockout lines to study loss-of-function effects.

These models are sequence-verified and available from commercial sources, providing reproducible tools for research. They allow precise control over genetic background, enabling mechanistic studies and drug screening.

Gene-edited cell models are used to validate the role of FGFR2 mutations in osteoblast differentiation. For example, comparing wild-type and S252W knock-in cells reveals differences in gene expression and mineralization. Knockout lines help identify downstream targets and pathways. These models are essential for functional genomics studies.

Isogenic pairs (wild-type vs. mutant) are used in high-throughput screens to identify compounds that selectively inhibit mutant FGFR2 signaling. This approach can uncover drugs that reverse the pathological phenotype. Additionally, resistance mechanisms to FGFR inhibitors can be studied by generating resistant cell lines through chronic exposure.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, are lethal only in cells with FGFR2 mutations. This can reveal novel therapeutic targets and biomarkers for patient stratification. Gene-edited models also enable the identification of secreted proteins that serve as biomarkers for disease progression.